Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report

por Patrick, Natalya, Bahlis, Nizar, Peters, Steven
Publicado 2023

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells

por Grad, Jennifer M., Bahlis, Nizar J., Boise, Lawrence H.
Publicado 2001

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation

por Shah, Shardule P., Nooka, Ajay K., Jaye, David L., Bahlis, Nizar J., Lonial, Sagar, Boise, Lawrence H.
Publicado 2016

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

por Bahlis, Nizar J., Costa, Luciano J., Facon, Thierry, Harousseau, Jean-Luc, Manier, Salomon, Perrot, Aurore, Touzeau, Cyrille, Mohty, Mohamad
Publicado 2023

Profiling Chromatin Accessibility at Single-cell Resolution

por Sinha, Sarthak, Satpathy, Ansuman T., Zhou, Weiqiang, Ji, Hongkai, Stratton, Jo A., Jaffer, Arzina, Bahlis, Nizar, Morrissy, Sorana, Biernaskie, Jeff A.
Publicado 2021

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

por Weisel, Katja, Bahlis, Nizar J, Rodríguez-Otero, Paula, Viqueira, Andrea, Wang, Shen-Wu, Sathiah, Sangeetha, Robinson, Douglas, O’brien, Thomas, Quach, Hang
Publicado 2023

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

por Rodríguez-Otero, Paula, Quach, Hang, Weisel, Katja, Viqueira, Andrea, Wang, Shen-Wu, Hamilton, Phineas T., Xie, Tao, O’brien, Thomas, Bahlis, Nizar J
Publicado 2023

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

por Touzeau, Cyrille, Bahlis, Nizar J, Maisel, Christopher, Karlin, Lionel, Nina Varshavsky-Yanovsky, Asya, Leip, Eric, Conte, Umberto, Viqueira, Andrea, Larson, Sarah M.
Publicado 2023

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

por Mateos, Maria-Victoria, Bahlis, Nizar J, Spencer, Andrew, Kaedbey, Rayan, Rodríguez-Otero, Paula, Harrison, Simon, Wong, Chihunt, Goodman, Grant, Nakamura, Rin, Choeurng, Voleak, Cooper, James, Trudel, Suzanne
Publicado 2023

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation

por Dash, Ajeeta B., Zhang, Jacob, Shen, Lei, Li, Bin, Berg, Deborah, Lin, Jianchang, Avet‐Loiseau, Hervé, Bahlis, Nizar J., Moreau, Philippe, Richardson, Paul G., Di Bacco, Alessandra
Publicado 2020

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

por Kinder, Michelle, Bahlis, Nizar J., Malavasi, Fabio, de Goeij, Bart, Babich, Alexander, Sendecki, Jocelyn, Rusbuldt, Joshua, Bellew, Kevin, Kane, Colleen, van de Donk, Niels W.C.J.
Publicado 2021

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

por Belch, Andrew, Bahlis, Nizar, White, Darrell, Cheung, Matthew, Chen, Christine, Shustik, Chaim, Song, Kevin, Tosikyan, Axel, Dispenzieri, Angela, Anderson, Kenneth, Brown, Diane, Robinson, Suzanne, Srinivasan, Shankar, Facon, Thierry
Publicado 2020

Amyloidosis and COVID-19: experience from an amyloid program in Canada

por Lewis, Ellen, Fine, Nowell, Miller, Robert J. H., Hahn, Christopher, Chhibber, Sameer, Mahe, Etienne, Tay, Jason, Duggan, Peter, McCulloch, Sylvia, Bahlis, Nizar, Neri, Paola, Jimenez-Zepeda, Victor H.
Publicado 2022

Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer

por Nikolic, Ana, Singhal, Divya, Ellestad, Katrina, Johnston, Michael, Shen, Yaoqing, Gillmor, Aaron, Morrissy, Sorana, Cairncross, J. Gregory, Jones, Steven, Lupien, Mathieu, Chan, Jennifer A., Neri, Paola, Bahlis, Nizar, Gallo, Marco
Publicado 2021

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

por Shah, Mrinal Y., Martinez-Garcia, Eva, Phillip, Jude M., Chambliss, Allison B., Popovic, Relja, Ezponda, Teresa, Small, Eliza C., Will, Christine, Phillip, Madonna P., Neri, Paola, Bahlis, Nizar J., Wirtz, Denis, Licht, Jonathan D.
Publicado 2016

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

por Yan, Xiaoyu, Xu, Xu Steven, Weisel, Katja C., Mateos, Maria‐Victoria, Sonneveld, Pieter, Dimopoulos, Meletios A., Usmani, Saad Zafar, Bahlis, Nizar J., Puchalski, Thomas, Ukropec, Jon, Bellew, Kevin, Ming, Qi, Sun, Steven, Zhou, Honghui
Publicado 2020

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

por Iida, Shinsuke, Ishikawa, Takayuki, Min, Chang Ki, Kim, Kihyun, Yeh, Su Peng, Usmani, Saad Z., Mateos, Maria-Victoria, Nahi, Hareth, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A., Gries, Katharine S., Qi, Ming, Bahlis, Nizar, Ito, Shigeki
Publicado 2021

CNV Radar: an improved method for somatic copy number alteration characterization in oncology

por Soong, David, Stratford, Jeran, Avet-Loiseau, Herve, Bahlis, Nizar, Davies, Faith, Dispenzieri, Angela, Sasser, A. Kate, Schecter, Jordan M., Qi, Ming, Brown, Chad, Jones, Wendell, Keats, Jonathan J., Auclair, Daniel, Chiu, Christopher, Powers, Jason, Schaffer, Michael
Publicado 2020

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

por Bahlis, Nizar J., Baz, Rachid, Harrison, Simon J., Quach, Hang, Ho, Shir-Jing, Vangsted, Annette Juul, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Coppola, Sheryl, Yang, Xiaoqing, Al Masud, Abdullah, Ross, Jeremy A., Bueno, Orlando, Kaufman, Jonathan L.
Publicado 2021

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

por Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.
Publicado 2019